戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e, for this reason, the paradigm for 'cancer differentiation therapy'.
2 t to alter leukemia-initiating cell fate for differentiation therapy.
3 a malignancy that can be cured clinically by differentiation therapy.
4 MT2-DKK1-beta-catenin node holds promise for differentiation therapy.
5  oncogenic driver and a promising target for differentiation therapy.
6 alpha regulation, unveiling a new avenue for differentiation therapy.
7  as a unique opportunity for intervention by differentiation therapy.
8 iency could be rational targets for leukemia differentiation therapy.
9 r cause of death despite the introduction of differentiation therapy.
10 teosarcoma and identify USP1 as a target for differentiation therapy.
11 ndergo cell cycle arrest, an approach termed differentiation therapy.
12 l system for investigating the principles of differentiation therapy.
13 yeloid leukemia cells refractory to retinoid differentiation therapy.
14 al studies toward the treatment of cancer by differentiation therapy.
15 get for enhancing AML responsiveness to ATRA differentiation therapies.
16 toxic chemotherapy with molecularly-targeted differentiation therapies.
17  synergistic effects of rejuvenation and pro-differentiation therapies.
18  processes, kinases are potential targets of differentiation therapies.
19 lopmental block of MRT and reveals potential differentiation therapies.
20 acterized by arrested differentiation making differentiation therapy a promising treatment strategy.
21 s of two stochastic models concerning glioma differentiation therapy, an alternative cancer treatment
22 ctivity can be modulated in the presence of 'differentiation therapy' and 'transcription therapy' age
23 reactivate PRDM1 expression as part of novel differentiation therapy approaches.
24                             However, current differentiation therapies are effective only to specific
25 d healing, whereas attenuating it could be a differentiation therapy-based approach for treating psor
26  and constructs a platform towards extending differentiation therapy by performing "dry" molecular bi
27 d leukemia cells may enhance the activity of differentiation therapy drugs for this type of leukemia.
28               To establish a system to study differentiation therapy drugs, we used the androgen-inde
29  as a robust tool for the discovery of novel differentiation therapies for cancer.
30 iating cells and novel targets applicable to differentiation therapies for glioblastoma.
31 rapeutic target for the development of novel differentiation therapies for patients with AML.
32                                    Effective differentiation therapy for acute myeloid leukemia (AML)
33  This interaction is the molecular target of differentiation therapy for acute promyelocytic leukaemi
34    All-trans-retinoic acid (RA) is used as a differentiation therapy for acute promyelocytic leukemia
35 R140Q could have potential applications as a differentiation therapy for cancer.
36 drug discovery or repositioning in leukaemia differentiation therapy for other subtypes of leukaemia
37 rder, hold substantial clinical potential as differentiation therapy for RMS and perhaps other solid
38 ich are spurring research regarding nontoxic differentiation therapy for this disease.
39 es proof-of-principle for inducing an MET as differentiation therapy for TICs and uncovers a role for
40                             In recent years, differentiation therapy has been proposed as an alternat
41              The best proof of principle for differentiation therapy has been the treatment of acute
42              Since the 1970s, the concept of differentiation therapy has been viewed as a promising a
43 e exquisite sensitivity of APL to ATRA-based differentiation therapy has not been extended to other o
44 ever, the successful clinical application of differentiation therapy has only been realized since the
45 uccess of all-trans-retinoic acid (RA)-based differentiation therapy in acute promyelocytic leukemia
46 11c provided surrogate imaging biomarkers of differentiation therapy in an acute promyelocytic leukem
47 ing approaches for cell cycle inhibition and differentiation therapy in cancer.
48 approach for identifying small molecules for differentiation therapy in cancer.
49 gr-1 targets may provide important tools for differentiation therapy in certain leukemic phenotypes.
50  of APL, presenting a potential paradigm for differentiation therapy in clinical oncology.
51 gnaling by PORCN inhibition holds promise as differentiation therapy in genetically defined human can
52 ur findings also underscore the potential of differentiation therapy in HCC.
53   These findings advance the concept of MDSC differentiation therapy in immuno-oncology.
54 C3 function represent a promising option for differentiation therapy in malignant tumors with dysregu
55 area of interest is chromatin remodeling and differentiation therapy, including agents such as all- r
56                Theoretically, the concept of differentiation therapy involves turning a cancer cell "
57                                              Differentiation therapy is an area of oncology that is i
58                                              Differentiation therapy is attracting increasing interes
59                                              Differentiation therapy is being developed as an additio
60 ute promyelocytic leukaemia(3), but whether 'differentiation therapy' is a generalizable therapeutic
61 btraction hybridization was combined with a "differentiation therapy" model of cancer in which human
62 and demonstrate the potential for epigenetic differentiation therapy of a solid tumour through EZH2 i
63 ered clinical trials as a potential drug for differentiation therapy of advanced prostate cancer.
64  dehydrogenase (IDH) invigorated interest in differentiation therapy of AML so that several new drugs
65                                  Advances in differentiation therapy of cancer are likely to depend o
66  APL has overnight become a paradigm for the differentiation therapy of cancer.
67 factors support the continued enthusiasm for differentiation therapy of leukemia in the future.
68 supraphysiological levels of this hormone in differentiation therapy of leukemic cells.
69 onse in keratinocytes, with implications for differentiation therapy of squamous cancer.
70 ddition of specific antiangiogenic agents to differentiation therapy or chemotherapy should be explor
71 trategy targeting CSCs by either employing a differentiation therapy or specifically delivering drugs
72                                         This differentiation therapy propelled interest in uncovering
73                                          The differentiation therapy, retinoic acid, is currently use
74 ion factor PU.1 or withdrawal of established differentiation therapies, some mature leukemia cells ca
75 te that ZNF117 is a promising target for GSC differentiation therapy through targeted delivery of CRI
76  by blocking Cyp26a1 in cell replacement/ESC differentiation therapy to treat neurodegenerative disea
77 ting certain genes and pathways involved in "differentiation therapy" used in the treatment of acute
78                                              Differentiation therapy utilizes our understanding of th
79   The potential therapeutic utility of HDACi differentiation therapy was established in three differe
80                            To discover novel differentiation therapies, we applied this approach to a
81 atically to all-trans retinoic acid mediated differentiation therapy, whereas others do not.
82 a hormone ligand is required for its action, differentiation therapy with ATRA may be self-limiting.
83 ectively, our data suggest that revisiting a differentiation therapy with forskolin in combination wi